Shengshi Junlian's Tumor Chemotaxis Enhanced BCMA CAR-T Clinical Study Has Excellent Efficacy

Multiple myeloma (MM) is a heterogeneous malignant plasma cell tumor and is one of the most common hematological malignancies. The number of new cases of MM in China in 2022 is 22,400. The first-line treatment of MM includes chemical drug combination therapy and autologous stem cell transplantation, etc., but most patients will inevitably relapse and progress to refractory after initial disease control. CAR-T (Chimeric antigen receptor T cell, chimeric antigen receptor T cell) therapy is a new cell therapy technology, which is considered to be the most effective technology for the treatment of relapsed/refractory multiple myeloma (r/r MM).

Shengshi Junlian cooperated with the team of West China Hospital, and through years of assiduous research, developed a new generation of CAR-T cell technology with better tumor targeting: tumor chemotaxis enhanced CAR-T cells. Combining this technology with high-affinity antibodies screened from the "300 billion-level diversity" biological drug library of Shengshi Junlian, the team successfully prepared CAR-T cells that simultaneously express tumor-targeting antibodies and tumor chemokine receptors. The CAR-T has shown significant tumor chemotaxis and tumor killing effects in preclinical studies. Compared with conventional second-generation CAR-T cells, the new CAR-T cells only need 1/4-1/10 dose to It can remove tumor cells very well. The dose reduction can bring two clinical benefits: 1) effectively reduce the immune storm (CRS) induced by conventional CAR-T therapy; 2) for those multiple myeloma patients who have undergone repeated treatment, the number and quality of immune cells are insufficient It is often impossible to obtain a large number of cells required for conventional CAR-T reinfusion through expansion, but using tumor tissue chemotaxis-enhanced CAR-T technology, due to the reduction in the number of reinfused CAR-T, these patients may be included treat.

The new generation of BCMA CAR-T prepared using tumor chemotaxis-enhanced CAR-T cell technology is undergoing Phase I clinical trials (IIT) in the Department of Hematology, West China Hospital, for relapsed/refractory multiple myeloma (r/r MM )Treatment. At present, 3 clinical trials of CAR-T low-dose group (lower than the conventional clinical dose) have been completed. Among the 3 r/r MM patients enrolled, only grade 1-2 toxicity occurred, and 2 of them reached Complete response (CR/sCR), showing very encouraging safety and efficacy. At this stage, this clinical trial is still in progress, and more patients will be enrolled. "May what we have learned become a medicine for curing diseases and saving lives." With this vision, Shengshi Junlian hopes to truly serve patients and human health.

This project is actively seeking external cooperation, and interested pharmaceutical companies are welcome to contact us.